Table 1. Patient characteristics with reference to the occurrence of CRBN gene genotypes (rs6768972 and rs1672753).
| Variable | CRBN n (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| rs6768972 |
p C |
rs1672753 |
P C |
|||||
| AA 34 (50) |
AC 29 (42,6) |
CC 5 (7,4) |
CC 5 (7,4) |
CT 24 (35,3) |
TT 39 (57,3) |
|||
| Sex | ||||||||
| Men | 21 (53,8) | 15 (38,5) | 3 (7,7) | 0,7187 | 2 (5,6) | 13 (33,3) | 24 (61,5) | 0,6082 |
| Women | 13 (44,8) | 14 (48,3) | 2 (6,9) | 0,0981 | 3 (10,3) | 11 (37,9) | 15 (51,7) | 0,120 |
| Age | ||||||||
| <65 | 25 (54,4) | 18 (39,1) | 3 (6,5) | 0,5817 | 4 (8,7) | 15 (32,6) | 27 (58,7) | 0,7104 |
| ≥65 | 9 (40,9) | 11 (50) | 2 (9,1) | 0,1250 | 1 (4,5) | 9 (40,9) | 12 (54,5) | 0,0998 |
| Smoking | ||||||||
| Non-smokers | 23 (50) | 19 (41,3) | 4 (8,7) | 0,6368 | 5 (10,9) | 15 (32,6) | 26 (56,5) | 0,6082 |
| Active smokers | 5 (41,7) | 7 (58,3) | - | 0,190 | - | 5 (41,7) | 7 (58,3) | 0,196 |
| Ex-smokers | 6 (60) | 3 (30) | 1 (10) | - | 4 (40) | 6 (60) | ||
| Exposure to carcinogenic factors | ||||||||
| Yes | 18 (72) | 6 (24) | 1 (4) | 0,0218 | 1 (4) | 4 (16) | 20 (80) | 0,0150 |
| No | 16 (37,2) | 23 (53,5) | 4 (9,3) | 0,318 | 4 (9,3) | 20 (46,5) | 19 (44,2) | 0,32 |
| Family history of cancer | ||||||||
| Yes | 14 (48,3) | 11 (37,9) | 4 (13,8) | 0,2074 | 4 (13,8) | 10 (34,5) | 15 (51,7) | 0,2079 |
| No | 20 (51,2) | 18 (46,2) | 1 (2,6) | 0,21 | 1 (2,6) | 14 (35,9) | 24 (61,5) | 0,210 |
| History of other cancers | ||||||||
| Yes | 2 (66,7) | 1 (33,3) | - | 0,7910 | - | 1 (33,3) | 2 (66,7) | 0,8686 |
| No | 32 (49,2) | 28 (43,1) | 5 (7,7) | 0,0828 | 5 (7,7) | 23 (35,4) | 37 (56,9) | 0,0642 |
| Diagnosis | ||||||||
| Secretory | 25 (43,1) | 28 (48,3) | 5 (8,6) | 0,0753 | 4 (6,9) | 24 (41,4) | 30 (51,7) | 0,0025 |
| Light chain disease | 8 (100) | - | - | 0,380 | - | - | 8 (100) | 0,479 |
| Non-secretory/plasmablastic | - | 1 (100) | - | 1 (100) | - | - | ||
| Non-secretory/pasmacytoma | 1 (100) | - | - | - | - | 1 (100) | ||
| Monoclonal protein class | ||||||||
| IgA | 9 (52,9) | 7 (41,2) | 1 (5,9) | 0,6655 | 1 (5,9) | 7 (41,2) | 9 (52,9) | 0,9848 |
| IgG | 17 (41,5) | 21 (51,2) | 4 (9,8) | 0,117 | 3 (7,3) | 17 (41,5) | 22 (53,7) | 0,0227 |
| Light chain type | ||||||||
| Lambda | 15 (55,6) | 9 (33,3) | 3 (11,1) | 0,3817 | 2 (7,4) | 10 (37) | 15 (55,6) | 0,9163 |
| Kappa | 18 (46,2) | 19 (48,7) | 2 (5,1) | 0,168 | 2 (5,1) | 14 (35,9) | 23 (59) | 0,051 |
| Durie-Salmon stage | ||||||||
| I | 2 (50) | 1 (25) | 1 (25) | 0,5681 | 1 (25) | 1 (25) | 2 (50) | 0,4491 |
| II | 3 (42,9) | 4 (57,1) | - | 0,204 | - | 4 (57,1) | 3 (42,9) | 0,227 |
| III | 29 (50,9) | 24 (42,1) | 4 (7) | 4 (7) | 19 (33,3) | 34 (59,7) | ||
| ISS stage | ||||||||
| 1 | 5 (33,3) | 7 (46,7) | 3 (20) | 0,2882 | 3 (20) | 5 (33,3) | 7 (46,7) | 0,3621 |
| 2 | 12 (54,5) | 9 (40,9) | 1 (4,54) | 0,265 | 1 (4,5) | 8 (36,4) | 13 (59,1) | 0,248 |
| 3 | 15 (51,7) | 13 (79,3) | 1 (3,4) | 1 (3,4) | 11 (37,9) | 17 (58,6) | ||
| Deletion17p | ||||||||
| Present | 5 (55,6) | 3 (33,3) | 1 (11,1) | 0,9044 | - | 4 (44,4) | 5 (55,6) | 0,6760 |
| Absent | 15 (53,6) | 11 (39,3) | 2 (7,1) | 0,0735 | 2 (7,2) | 10 (35,7) | 16 (57,1) | 0,144 |
| Translocation t(4;14) | ||||||||
| Present | 2 (33,3) | 4 (66,7) | - | 0,2563 | - | 4 (66,7) | 2 (33,3) | 0,2655 |
| Absent | 18 (58,1) | 10 (32,2) | 3 (9,7) | 0,262 | 2 (6,5) | 10 (32,2) | 19 (61,3) | 0,259 |
| Translocation t(4;16) | ||||||||
| Present | - | - | 1 (100) | 0,0030 | - | 1 (100) | - | 0,4299 |
| Absent | 20 (55,6) | 14 (38,9) | 2 (5,6) | 0,489 | 2 (5,6) | 13 (36,1) | 21 (58,3) | 0,209 |
| Renal function | ||||||||
| A | 29 (50,9) | 23 (40,4) | 5 (8,7) | 0,4832 | 5 (8,7) | 19 (33,4) | 33 (57,9) | 0,5049 |
| B | 5 (45,5) | 6 (54,5) | - | 0,145 | - | 5 (45,5) | 6 (54,5) | 0,140 |
| Stage of chronic kidney disease | ||||||||
| G1 | 15 (46,9) | 15 (46,9) | 2 (6,2) | 0,8964 | 3 (9,3) | 11 (34,3) | 18 (59,4) | 0,8797 |
| G2 | 8 (53,3) | 5 (33,3) | 2 (13,4) | 0,260 | 2 (13,4) | 4 (26,6) | 9 (60) | 0,266 |
| G3a | 3 (60) | 1 (20) | 1 (20) | - | 2 (40) | 3 (60) | ||
| G3b | 3 (50) | 3 (50) | - | - | 3 (50) | 3 (50) | ||
| G4 | 3 (60) | 2 (40) | - | - | 1 (20) | 4 (80) | ||
| G5 | 2 (40) | 3 (60) | - | - | 3 (60) | 2 (40) | ||
| Performance status | ||||||||
| 0 | 5 (50) | 2 (20) | 3 (30) | 0,0719 | 3 (30) | 2 (20) | 5 (50) | 0,6871 |
| 1 | 9 (45) | 9 (45) | 2 (10) | 0,382 | 1 (5) | 8 (40) | 11 (55) | 0,204 |
| 2 | 15 (51,7) | 14 (48,3) | - | - | 12 (41,4) | 17 (59,6) | ||
| 3 | 5 (55,6) | 4 (44,4) | - | 1 (11,1) | 2 (22,2) | 6 (66,7) | ||
| Body weight loss before treatment | ||||||||
| Yes | 17 (51,5) | 15 (45,5) | 1 (3) | 0,4112 | 2 (5,7) | 12 (34,3) | 19 (54,3) | 0,9199 |
| No | 17 (48,6) | 14 (40) | 4 (11,4) | 0,160 | 3 (9) | 12 (30,3) | 20 (60,6) | 0,0495 |
| 5% | 7 (53,8) | 5 (38,5) | 1 (7,7) | 0,4082 | 1 (7,7) | 4 (30,8) | 8 (61,5) | 0,8448 |
| 10% | 10 (50) | 10 (50) | - | 0,227 | 1 (5) | 8 (40) | 11 (55) | 0,101 |
| Anemia grade before treatment (according to WHO) | ||||||||
| Absent | 13 (59,1) | 8 (36,4) | 1 (4,5) | 0,1334 | 1 (4,5) | 7 (31,8) | 14 (63,4) | 0,7465 |
| I (mild) | 6 (30) | 10 (50) | 4 (20) | 0,393 | 3 (15) | 9 (45) | 8 (40) | 0,264 |
| II (moderate) | 11 (61,1) | 7 (38,9) | - | 1 (5,6) | 5 (27,8) | 12 (66,7) | ||
| III (severe) | 4 (66,7) | 2 (33,3) | - | - | 2 (33,3) | 4 (66,7) | ||
| IV (life-threatening) | - | 2 (100) | - | - | 1 (50) | 1 (50) | ||